Article

Gilead's deal of a lifetime

Nature Biotechnology (Impact Factor: 41.51). 06/2009; 27(5):423. DOI: 10.1038/nbt0509-423
Source: PubMed

ABSTRACT

Gilead Sciences' ascent to the upper echelon of biotech centered around one very savvy acquisition that launched an HIV franchise.

Download full-text

Full-text

Available from: Christopher Thomas Scott, Dec 09, 2014
This research doesn't cite any other publications.